糖尿病临床研究

　　【摘要】　目的　观察每日口服10 mg阿托伐他汀对原发性高血压合并IGT患者炎症因子水平的影响。 方法　36例原发性高血压合并糖耐量异常患者(EH+IGT组)口服阿托伐他汀10 mg ，1次/晚。另选择 36例体检者作为对照(NC)组。检测两组FPG、2hPG、胰岛素抵抗指数(HOMA-IR)及血清炎症因子水平的变化。结果 　EH+IGT组均完成试验。口服10 mg阿托伐他汀治疗8周末BP、2 hPG、HOMA-IR、肿瘤坏死因子α(TNF-α)及(白细胞介素-6)IL-6下降[BP(159.71±12.25)/(98.67±12.06) vs (131.89±10.72)/(81.76±9.03) mmHg;2hPG (8.39±0.65) vs (6.76±1.19)mmol/L; HOMA-IR (3.11±1.95) vs (2.30 ±1.25);TNF-α(32.11 ±5.36) vs (24.29±4.57) ng/ L;IL-6 (112.37 ±24.48) vs (70.47±13.30)ng/L] (P<0.01)。结论 每日口服10 mg阿托伐他汀可降低高血压合并糖耐量异常患者的血清炎症因子水平。

　　【关键词】　阿托伐他汀;原发性高血压;糖耐量异常;肿瘤坏死因子-α;白细胞介素-6;

　　【Abstract】 Objective　To study the effect s of Atorvastatin 10mg daily on plasma inflammatory cytokines in hypertension patients with impaired glucose tolerance. Methods A total of 36 EH patients with IGT recieved Atorvastatin 10 mg, qn. 36 healthy adults served as controls. The levels of fasting blood glucose, postprandial -2-hour blood glucose, HOMA-IR, inflammatory cytokines of each group were tested before and after treatment. Results All the participants in EH+IGT group finished the study. Compared with control group, BP, 2hPG, HOMA-IR, TNF-α and IL-6 were decreased significantly [BP(159.71±12.25)/(98.67±12.06) vs (131.89±10.72)/(81.76±9.03) mmHg];2hPG (8.39±0.65) vs (6.76±1.19)mmol/L; HOMA-IR (3.11±1.95) vs (2.30 ±1.25);(32.11 ±5.36) vs (24.29±4.57) ng/ L;(112.37 ±24.48) vs (70.47±13.30)ng/L] (P<0.01). Conclusion　 Atorvastatin 10mg daily could decrease the level of inflammatory cytokines in hypertension patients with impaired glucose tolerance.

　　【Key words】 Atorvastatin; Essential hypertension(EH);Impaired glucose tolerance(IGT); Tumor necrosis factor-α(TNF-α); Interleukin-6(IL-6)